Oncology Healthcare & Pharmaceuticals News

European Commission Approves Roche’s Subcutaneous Lunsumio for Relapsed or Refractory Follicular Lymphoma

Roche

European Commission has granted conditional approval for the subcutaneous version of Roche’s bispecific antibody, Lunsumio (mosunetuzumab). This new formulation for relapsed or refractory follicular lymphoma offers high rates of deep and durable responses while reducing treatment administration time from several hours to approximately one minute. This enhanced flexibility promises a better treatment experience for patients and streamlined care delivery in clinics.

Clinical Trials Autoimmune Diseases Healthcare & Pharmaceuticals News

New 48-Week Data Shows TREMFYA® (guselkumab) Substantially Inhibits Joint Damage in Psoriatic Arthritis

JohnsonAndJohnson

New long-term data from the Phase 3b APEX study confirms that TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to substantially inhibit the progression of structural joint damage in patients with active psoriatic arthritis, with results sustained through 48 weeks.

Business Healthcare & Pharmaceuticals News

Merck to Acquire Cidara Therapeutics for $9.2 Billion, Gaining Late-Stage Antiviral Agent CD388

Merck MSD

Merck has announced a definitive agreement to acquire Cidara Therapeutics for approximately $9.2 billion in an all-cash deal. The strategic acquisition centers on Cidara’s lead candidate, CD388, a potentially first-in-class, long-acting antiviral designed for the universal prevention of influenza A and B, which is currently in Phase 3 trials. The transaction is expected to close in the first quarter of 2026.

Business Healthcare & Pharmaceuticals News

Merck Group Q3 2025: Strong Organic Growth Across All Sectors

Merck KGaA News

Merck delivered solid Q3 2025 results, achieving 5.2% organic growth that successfully offset significant currency headwinds. This resilience was seen across all three business sectors, driven by strong demand for Process Solutions in Life Science, the new Rare Diseases franchise in Healthcare, and AI-driven demand for Semiconductor Solutions.

Genomics Artificial Intelligence Healthcare & Pharmaceuticals News

SOPHiA GENETICS and Complete Genomics Partner to Integrate AI Oncology Assays with New Sequencing Platform

SOPHiA GENETICS NEWS

SOPHiA GENETICS (NASDAQ: SOPH) and Complete Genomics have announced a collaboration to broaden access to precision oncology testing. The partnership will integrate the AI-powered SOPHiA DDMâ„¢ platform with Complete Genomics’ new DNBSEQ-T1+ sequencing system. This will provide a streamlined, sample-to-report workflow for the renowned MSK-IMPACT® (solid tumor) and MSK-ACCESS® (liquid biopsy) assays.

Clinical Trials Healthcare & Pharmaceuticals News Oncology

Roche’s Fenebrutinib Shows “Unprecedented” Phase III Success in Both Relapsing and Progressive Multiple Sclerosis

Roche

Roche announced today that its investigational oral medication, fenebrutinib, has met primary endpoints in two separate, pivotal Phase III studies for both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The drug significantly reduced relapse rates in RMS and slowed disability progression in PPMS, positioning it as a potential first-in-class, high-efficacy oral treatment for the two most common forms of the disease.

Clinical Trials Healthcare & Pharmaceuticals News

Merck’s Oral PCSK9 Inhibitor, Enlicitide, Shows Significant LDL-C Reduction in Phase 3 CORALreef HeFH Trial

Merck MSD

Merck announced promising results from its pivotal Phase 3 CORALreef HeFH trial. The study found that enlicitide, an investigational, once-daily oral PCSK9 inhibitor, significantly reduced low-density lipoprotein cholesterol (LDL-C) in adults with heterozygous familial hypercholesterolemia (HeFH). These late-breaking data were presented at the AHA Scientific Sessions 2025.